Therefore, it is particularly compelling to realise how HT affects these two significant targets of cancer immune evasion mechanisms (PD-L1 and NLRC5) when considering the integration of HT into immunotherapy strategies for treating ovarian cancer. The gene discussed is NLRC5; the disease is ovarian carcinoma.